

Our Ref : Geno/Cir/ 1623

08th September, 2025

Dear Valued Channel Partners,

Subject: GST Rate Transition – Ensuring Business Continuity and Seamless Operations

Dear Channel Partners,

We hope this communication finds you in good health and high spirits.

This is to inform you that as per the recent notification by the **GST Council**, the applicable GST rate on pharmaceutical products will be reduced from existing rates, effective from **22nd Sept25**.

We appreciate the intent of this reform, which is aimed at enhancing affordability and access to healthcare. To ensure smooth implementation, we request your attention to the following.

1. Input Tax Credit (ITC) Assurance

You will retain **full input credit** on inventory purchased at the currently prevailing GST rate. While sales may now occur at lower GST rate, your accumulated ITC remains valid and claimable. No financial loss will be incurred.

2. Operational Continuity & Inventory Planning

We encourage you to **maintain normal purchasing patterns and inventory levels** in line with prevailing demand. This will help prevent supply disruptions and ensure uninterrupted access to essential medicines to the patients.

3. Billing System & Compliance Updates

From **22nd September 2025**, all invoices must reflect the **revised GST rate**. Please ensure your billing systems are updated accordingly. A detailed product-wise price list will be shared with you shortly to facilitate accurate billing and onward communication with your customers and retailers.


4. Passing on the Benefits

We are collectively responsible for ensuring that the **benefits of the GST reduction** reach the end consumer by way of **price corrections** in line with regulatory expectations **from 22nd Sept'25**.

We are closely monitoring this transition and remain available for any clarifications or support you may require. Thank you for your continued cooperation and trust.

Thanks & Regards

For GENO PHARMACEUTICALS PVT LTD



AUTHORISED SIGNATORY